Business

Zydus Cadila gets USFDA nod to market generic tension headache tablets

The company has received final approval to market Butalbital, Acetaminophen and Caffeine tablets in strengths of 50mg/325mg/40 mg, Zydus Cadila said in a statement.

From our online archive

NEW DELHI: Drug firm Zydus Cadila on Saturday said it has received final approval from the US health regulator to market generic Butalbital, Acetaminophen and Caffeine combination tablets to treat symptoms of tension headaches.

The company has received final approval from the United States Food and Drug Administration (USFDA) to market Butalbital, Acetaminophen and Caffeine tablets in strengths of 50mg/325mg/40 mg, Zydus Cadila said in a statement.

The drug will be manufactured at Nesher Pharma's manufacturing facility at St.Louis in the US, it added.

This combination medication is used to treat symptom complex of tension (or muscle contraction) headaches, Zydus Cadila said.

The group now has 294 approvals and has filed over 390 abbreviated new drug applications (ANDAs) since the commencement of the filing process, it added.

‘Very perturbed’, HC says SIR draft roll cannot be basis for deleting voters’ names without hearing

Congress' Venugopal flags ‘rushed scrutiny’ of FCRA Bill, seeks Speaker Om Birla’s intervention

SC upholds Calcutta HC order refusing access to frozen TMC bank accounts amid symbol dispute

Rahul Gandhi asks who at EC ordered ‘illegal’ Form 6 change, whether TCS was pressured

PM Modi speaks to Captain Smit Machchhar's family, hails injured pilot as 'hero'